Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

China flag China · Delayed Price · Currency is CNY
51.37
-1.62 (-3.06%)
Mar 19, 2026, 11:54 AM CST
Market Cap43.25B -0.3%
Revenue (ttm)6.56B -3.5%
Net Income612.15M -36.1%
EPS0.71 -35.6%
Shares Out855.14M
PE Ratio74.20
Forward PE52.98
Dividend0.30 (0.57%)
Ex-Dividend DateJun 17, 2025
Volume4,871,100
Average Volume8,307,150
Open55.60
Previous Close52.99
Day's Range51.25 - 55.60
52-Week Range41.61 - 71.90
Beta0.68
RSI31.63
Earnings DateMar 30, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,251
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300347
Full Company Profile

Financial Performance

In 2024, SHE:300347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial Statements